San Francisco, United States
Symic Bio, founded in 2012, is a pioneering company in the Biotechnology and Health Care industries, headquartered in the United States. The company has positioned itself as a leader in creating a new category of therapeutics based on extracellular matrix (ECM) biology, an approach that holds significant potential for treating various diseases. Their focus is on developing ECM-specific compounds that mimic the protective effects of natural proteoglycans — crucial components in tissue maintenance and healing.
With a proprietary library of compounds, Symic Bio has shown promise in managing both acute and chronic conditions by targeting the ECM directly to reduce inflammation and tissue degradation. This unique approach could address unmet clinical needs in areas such as osteoarthritis and post-operative healing.
The company received an $11.00M Series C investment on April 25, 2019, backed by investors like Cell Innovation Partners, Shinsei Bank, and ReproCELL. This support underscores investor confidence in Symic Bio's innovative therapeutic solutions and market potential.
